Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection

MT Newswires Live

2024/09/19

Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.

The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.

The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.

Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2468410519"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468410519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468410519?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 12:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468410519","market":"us","top_or_hot":-1,"title":"Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection","media":"MT Newswires Live","content":"<html><body><p> Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.</p><p>The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.</p><p>The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.</p><p>Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-19 12:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.</p><p>The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.</p><p>The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.</p><p>Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468410519","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468410519","pubTimestamp":1726721145,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Yifan Pharmaceutical  unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.Price : 10.31, Change: +0.17, Percent Change: +1.68%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0077":"质押式回购","BK0191":"维生素","BK0197":"中小创蓝筹","002019":"亿帆医药","BK0239":"医药制造","BK0185":"二线龙头","BK0070":"员工持股"},"translate_title":"亿帆药业法莫替丁注射液上市获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002019":0.9},"content_text":"Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}